Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

被引：0

作者：

Yildirim, Hasan Cagri ^{[1
]}

Bayram, Ertugrul ^{[2
]}

Chalabiyev, Elvin ^{[3
]}

Majidova, Nargiz ^{[4
]}

Avci, Tugay ^{[5
]}

Guzel, Halil Goksel ^{[6
]}

Kapar, Caner ^{[7
]}

Uzun, Mehmet ^{[8
]}

Perkin, Perihan ^{[9
]}

Akgul, Fahri ^{[10
]}

Yildirim, Saadet Sim ^{[11
]}

Sali, Seda ^{[12
]}

Yildiz, Anil ^{[13
]}

Kazaz, Seher Nazli ^{[14
]}

Hendem, Engin ^{[15
]}

Arcagok, Murat ^{[16
]}

Tufan, Gulnihal ^{[17
]}

Yildirim, Umit ^{[18
]}

Akgul, Omer Faruk ^{[19
]}

Arslan, Cagatay ^{[20
]}

Taban, Hakan ^{[21
]}

Sahin, Eren ^{[22
]}

Caglayan, Melek ^{[23
]}

Esen, Ramazan ^{[18
]}

Oksuzoglu, Berna ^{[17
]}

Guven, Deniz Can ^{[3
]}

Kaplan, Muhammet Ali ^{[16
]}

Araz, Murat ^{[15
]}

Basaran, Mert ^{[13
]}

Cubukcu, Erdem ^{[12
]}

Gokmen, Erhan ^{[11
]}

Cicin, Irfan ^{[10
]}

Algin, Efnan ^{[9
]}

Semiz, Huseyin Salih ^{[8
]}

Tural, Deniz ^{[7
]}

Ozturk, Banu ^{[6
]}

Erdogan, Atike Pinar ^{[5
]}

Sari, Murat ^{[4
]}

Kara, Oguz ^{[2
]}

Erman, Mustafa ^{[3
]}

机构：

[1] Nigde Educ & Res Hosp, Dept Med Oncol, Nigde, Turkiye

[2] Cukurova Univ, Fac Med, Dept Med Oncol, Adana, Turkiye

[3] Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkiye

[4] Marmara Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye

[5] Celal Bayar Univ, Fac Med, Dept Med Oncol, Manisa, Turkiye

[6] Antalya Educ & Res Hosp, Dept Med Oncol, Antalya, Turkiye

[7] Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkiye

[8] Eylul Univ, Fac Med 9, Dept Med Oncol, Izmir, Turkiye

[9] Yildirim Beyazit Univ, Bilkent State Hosp, Dept Med Oncol, Ankara, Turkiye

[10] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkiye

[11] Ege Univ, Fac Med, Dept Med Oncol, Izmir, Turkiye

[12] Uludag Univ, Fac Med, Dept Med Oncol, Bursa, Turkiye

[13] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkiye

[14] Med Pk Hosp, Dept Med Oncol, Trabzon, Turkiye

[15] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkiye

[16] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye

[17] Univ Hlth Sci, Dr AY Ankara Oncol Res & Educ Hosp, Dept Med Oncol, Ankara, Turkiye

[18] Yuzuncu Yil Univ, Fac Med, Dept Med Oncol, Van, Turkiye

[19] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkiye

[20] Medicalpoint Hosp, Dept Med Oncol, Izmir, Turkiye

[21] Samsun Training & Res Hosp, Dept Med Oncol, Samsun, Turkiye

[22] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkiye

[23] Selcuk Univ, Fac Med, Dept Med Oncol, Konya, Turkiye

来源：

JOURNAL OF CHEMOTHERAPY | 2024年

关键词：

Non-clear cell renal cell carcinoma; sunitinib; pazopanib; TKIs; rare tumors; papillary RCC; OPEN-LABEL; 1ST-LINE PAZOPANIB; MULTICENTER; INHIBITOR; THERAPY; CANCER;

D O I：

10.1080/1120009X.2024.2403051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. Pazopanib and sunitinib treatments show similar progression free survival, overall survival and objective response rate.IMDC risk group, liver metastasis, sarcomatoid component and de novo metastatic disease were determined as prognostic factors

引用

页数：12

共 50 条

[41] Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
Xu K.Y.
Wu S.
Biomarker Research, 3 (1)
[42] Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
Tykodi, Scott S.
Gordan, Lucio N.
Alter, Robert S.
Arrowsmith, Edward
Harrison, Michael Roger
Percent, Ivor John
Singal, Rakesh
Van Veldhuizen, Peter J.
George, Daniel J.
Hutson, Thomas E.
Zhang, Joshua
Zoco, Jesus
Johansen, Jennifer L.
Kalebasty, Arash Rezazadeh
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[43] First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
Bersanelli, M.
Maines, F.
Facchini, G.
Gelsomino, F.
Zustovich, F.
Santoni, M.
Verri, E.
De Giorgi, U.
Masini, C.
Morelli, F.
Vitale, M. G.
Sava, T.
Prati, G.
Librici, C.
Fraccon, A. P.
Fornarini, G.
Maruzzo, M.
Leonardi, F.
Caffo, O.
Buti, S.
ANNALS OF ONCOLOGY, 2016, 27
[44] First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
Bersanelli, M.
Maines, F.
Facchini, G.
Gelsomino, F.
Zustovich, F.
Santoni, M.
Verri, E.
De Giorgi, U.
Masini, C.
Morelli, F.
Vitale, M. G.
Sava, T.
Prati, G.
Librici, C.
Fraccon, A. P.
Fornarini, G.
Maruzzo, M.
Leonardi, F.
Caffo, O.
Buti, S.
ANNALS OF ONCOLOGY, 2016, 27
[45] Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.
Yildiz, Ibrahim
Ekenel, Meltem
Altman, Tuley
Kocar, Muharrem
Uysal, Mukremin
Kanitez, Metin
Bayoglu, Vedat
Varol, Umut
Tural, Deniz
Avcl, Nilufer
Kaplan, Muhammet All
Surmeli, Zeki
Dede, Isa
Ulas, Arife
Yazici, Ozan
Basaran, Mert
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[46] Circulating cytokines and angiogenic factors (CAFs) in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: Results from a phase II clinical trial
Bilen, Mehmet Asim
Zurita, Amado J.
Ilias-Khan, Nasreen A.
Chen, Hsiang-Chun
Wang, Xuemei
Hodges, Sherie
Lim, Zita D.
Jonasch, Eric
Khakoo, Aarif Yusuf
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[47] Current treatment approach to non-clear cell renal carcinoma
Timofeev, I. V.
ONKOUROLOGIYA, 2015, 11 (04): : 24 - 33
[48] A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)
Hutson, Thomas E.
Michaelson, M. Dror
Kuzel, Timothy M.
Agarwal, Neeraj
Molina, Ana M.
Hsieh, James J.
Vaishampayan, Ulka N.
Xie, Sharon
Bapat, Urmi
Jain, Rohit K.
Fishman, Mayer N.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[49] Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma
Fujita, Tetsuo
Hirayama, Takahiro
Ishii, Daisuke
Matsumoto, Kazumasa
Yoshida, Kazunari
Iwamura, Masatsugu
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (04) : 394 - 398
[50] The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
Naik, Priyanka
Dudipala, Harshitha
Chen, Yu-Wei
Rose, Brent
Bagrodia, Aditya
Mckay, Rana R.
THERAPEUTIC ADVANCES IN UROLOGY, 2024, 16

← 1 2 3 4 5 →